Abstract
A 43-year-old woman underwent breast-conserving therapy for right breast cancer with multiple liver metastases (pT3N3aM1, stage IV, ER (-), PgR (-), HER2 (3+)), in November, 2002. Following surgery, she received combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab weekly. During therapy, no serious side effects and only grade 1 nausea were observed; after 3 courses, therapy was safely continued on an outpatient basis. Metastatic liver tumors responded to the treatment, and they completely disappeared on an abdominal CT 5 months later. In addition, all elevated tumor markers in serum decreased to the normal range. No new metastatic or recurrent lesions were found 14 months after surgery. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of breast cancer patients with liver metastasis.
MeSH terms
-
Administration, Oral
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / secondary
-
Carcinoma, Ductal, Breast / surgery
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Docetaxel
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Hepatic Artery
-
Humans
-
Infusion Pumps, Implantable
-
Infusions, Intra-Arterial
-
Liver Neoplasms / drug therapy
-
Liver Neoplasms / secondary*
-
Mastectomy, Segmental*
-
Taxoids / administration & dosage
-
Tegafur / administration & dosage
-
Trastuzumab
-
Uracil / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Drug Combinations
-
Taxoids
-
UFT(R) drug
-
Tegafur
-
Docetaxel
-
Uracil
-
Cyclophosphamide
-
Trastuzumab